II. Mechanism

  1. Humanized mouse Monoclonal Antibody to RSV

III. Indications: Based on AAP guidelines

  1. Chronic lung disease in age <2 years
    1. Medication treatment within 6 months of RSV season start
  2. Hemodynamically significant Congenital Heart Disease in age <2 years
  3. Consider in infants with severe Immunodeficiency
  4. Preterm Infants during their first RSV season
    1. Gestational age at birth <28 weeks (Give during first RSV season)
    2. Gestational age at birth 28-32 weeks who are under age 6 months during RSV season
    3. Gestational age 32-35 weeks with 2 risk factors:
      1. Day care attendance
      2. Siblings under 5 years of age
      3. Congenital airway abnormality
      4. Congenital neuromuscular disease

IV. Dosing

  1. Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)

V. Efficacy

  1. Decreases hospitalizations by 45 to 55%

VI. References

  1. Pickering (2009) Red Book, AAP, Elk Grove Village, p. 560

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: palivizumab (C0672596)

Definition (NCI) A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.
Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH C111186
SnomedCT 108725001, 386900007
English palivizumab, palivizumab (medication), PALIVIZUMAB, palivizumab [Chemical/Ingredient], Palivizumab (product), Palivizumab (substance), Palivizumab, PALI
Spanish palivizumab (producto), palivizumab (sustancia), palivizumab

Ontology: Synagis (C0723567)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH C111186
English Synagis, palivizumab (Synagis), synagis, MedImmune brand of palivizumab, Abbott brand of palivizumab

Ontology: Respiratory Syncytial Virus Vaccines (C0887894)

Definition (MSH) Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022261
Swedish RSV-vacciner
Czech RSV vakcíny, viry respirační syncyciální - vakcíny
Finnish RSV-rokotteet
Russian VAKTSINY RESPIRATORNO-SINTSITIAL'NOVIRUSNYE, RESPIRATORNO-SINTSITIAL'NOVIRUSNYE VAKTSINY, ВАКЦИНЫ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОВИРУСНЫЕ, РЕСПИРАТОРНО-СИНЦИТИАЛЬНОВИРУСНЫЕ ВАКЦИНЫ
Japanese RSウイルスワクチン, 呼吸シンチウムウイルスワクチン, RSVワクチン, ワクチン-RSV, ワクチン-RSウイルス
English Respiratory Syncytial Virus Vaccines [Chemical/Ingredient], respiratory syncytial virus vaccines, rsv vaccine, RSV Vaccines, Respiratory Syncytial Virus Vaccines, Vaccines, RSV
Polish Szczepionki przeciw wirusowi RS, Szczepionki przeciw wirusowi syncytialnemu układu oddechowego, Szczepionki przeciw zakażeniu wirusem RS, Szczepionki RSV
Portuguese Vacinas contra Rsv, Vacinas RSV, Vacinas contra Vírus Sincicial Respiratório
French Vaccins anti-RSV, Vaccins anti-virus respiratoire syncytial, Vaccins contre RSV, Vaccins contre virus respiratoire syncytial
German Impfstoffe, RSV-, RSV-Impfstoffe, RSV-Vakzinen, Respiratory-Syncytial-Virus-Vakzinen
Italian Vaccini contro il virus respiratorio sinciziale
Spanish Vacunas VSR, Vacunas contra Virus Sincitial Respiratorio